by Karen Madsen
Previous clinical studies have shown a promising role of fecal microbiota transplantation to induce remission in ulcerative colitis and maintain steroid-induced Crohn’s disease remission. A new double-blind, placebo-controlled trial found fecal microbiota transplantation is not effective at inducing clinical or endoscopic remission in adults with Crohn’s disease.
by GMFH Editing Team
Significant strides have been made in our comprehension of the role of the gut microbiome in health and disease throughout the year 2022. We invite you to take a closer look at the "2022 Year at a Glance" report and learn about the groundbreaking discoveries made.
by Andreu Prados
While fecal microbiota transplants are recommended for multiple recurrent Clostridioides difficile infection, their use in clinical practice is hindered by a lack of regulation and understanding of the underlying ecological dynamics. This article covers major challenges for the treatment in transitioning from bench to bedside, from the scientific, clinical and regulatory perspectives (Part 6).
by Andreu Prados
Clostridioides difficile infection is a common cause of diarrhea in both the hospital and community settings, with C. difficile recurrence one of the most challenging outcomes to address. This article focuses on the factors that predict long-term complications of C. difficile infection and what can be done in clinical practice to minimize them (Part 5).
by Konstantina Zafeiropoulou
Just one month before friends and families gather around the Christmas table, November is here to bring awareness around Clostridioides difficile infection, and the importance of microbiota-derived treatments. With this post, all of us in GMFH aim to highlight the importance of protecting ourselves and families and stopping the spread of this potentially deadly infection.
by Andreu Prados
Correcting the altered gut microbiome is an important goal in Clostridioides difficile management, but the matter is not addressed by mainstream treatments with antibiotics. This article focuses on where fecal microbiota transplantation and investigational microbiota-based therapeutics stand for C. difficile infection (Part 3)
by Andreu Prados
Clostridioides difficile infection is a common cause of diarrhea, not only in hospitals but also in outpatient settings. This article focuses on the diagnosis and treatment of C. difficile infection and includes an updated summary of literature on the latest guidelines (Part 2).
In a series of 7 webinar this programme will develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches.
by Andreu Prados
Clostridioides difficile infection is the most frequent cause of antibiotic-associated diarrhea in the hospital setting that has increased in severity. This article looks at the risk factors for developing C. difficile-associated disease, the spectrum of manifestations and the impact of the COVID-19 pandemic on the occurrence of C. difficile infection.
by GMFH Editing Team
GMFH continue to cover the important progress made in our knowledge of the gut microbiota's impact on wellbeing and disease.
